In August 2017, the U.S. Food and Drug Administration issued a historic action making the first gene therapy available in the United States, ushering in a new approach to the treatment of cancer and other serious and life-threatening diseases. The life-changing potential of gene therapy products is undeniable, but the cost, which could be 20 or 30 times the annual wages of the typical American, according to the director of the Center for Health Policy and Outcomes at the Memorial Sloan Kettering Cancer Center, will dramatically limit their reach.
Villanova University is poised to make its own contributions to gene and cell therapy through NovaCell, the Center for Cellular Engineering. Founded in 2018, NovaCell’s mission is to lead efforts to improve cell and gene therapy products, and the bioprocesses used to make them.
Villanova is the ideal location for the Center given its proximity to major medical research hospitals, as well as pharmaceutical companies working on cell therapy products.
Read the official press release about the launch of NovaCell, the Center for Cellular Engineering.